Insider Selling: BeOne Medicines (NASDAQ:ONC) COO Sells 280 Shares

Key Points

• BeOne Medicines COO Xiaobin Wu sold 280 shares at an average price of $380, generating $106,400 in proceeds. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, following several larger sales in June.
• ONC traded at $372.49, near its 52-week high of $385.22, with a market capitalization of approximately $40.9 billion. The company recently reported quarterly EPS of $2.05 and revenue of $1.71 billion, exceeding analyst expectations.
• Analysts maintain a broadly positive view, with a consensus rating of “Buy” and an average price target of $402.14. Institutional investors own about 48.55% of the company’s stock.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 280 shares of the company's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The stock was sold at an average price of $276.26, for a total transaction of $356,927.92.
• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The stock was sold at an average price of $266.76, for a total transaction of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Price Performance

ONC traded down $3.31 during trading on Thursday, reaching $372.49. The company's stock had a trading volume of 225,066 shares, compared to its average volume of 293,355. The company has a market cap of $40.89 billion, a price-to-earnings ratio of 65.58 and a beta of 0.49. The firm has a fifty day simple moving average of $321.55 and a two-hundred day simple moving average of $310.79. BeOne Medicines Ltd. - Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. As a group, analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post 8.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ONC. Royal Bank Of Canada reduced their price target on BeOne Medicines from $451.00 to $450.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Citizens Jmp upped their price objective on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a "market outperform" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on shares of BeOne Medicines from $415.00 to $425.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 18th. Finally, TD Cowen boosted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BeOne Medicines has an average rating of "Buy" and a consensus price target of $402.14.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new position in shares of BeOne Medicines during the second quarter worth $455,000. Rhumbline Advisers acquired a new position in BeOne Medicines during the 2nd quarter worth about $275,000. Arrowstreet Capital Limited Partnership acquired a new position in BeOne Medicines during the 2nd quarter worth about $505,000. Invesco Ltd. purchased a new position in BeOne Medicines during the 2nd quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $68,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source